Pediatric Endocrinology Diabetes and Metabolism

Terapia hormonem wzrostu u pacjenta z brachydaktylią – opis przypadku wraz z przeglądem literatury

Michał Erazmus 1
,
Ewa Witkowska 1
,
Dorota Czapczak 2, 3
,
Ewelina Witkowska 3
,
Beata Pyrżak 1
  1. Department of Paediatrics and Endocrinology, Medical University of Warsaw, Poland
  2. Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Poland
  3. Laboratory of Genetics University Center of Laboratory Medicine, Medical University of Warsaw, Poland
Pediatr Endocrinol Diabetes Metab 2026; 32 (2):
DOI: https://doi.org/10.5114/pedm.2026.161125
Data publikacji online: 2026/05/19
Plik artykułu
0416_Recombinant growth hormone.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
1. Temtamy SA, Aglan MS. Brachydactyly. Orphanet J Rare Dis 2008; 3: 15. doi: 10.1186/1750-1172-3-15.
2. David A, Vincent M, Quéré MP, et al. Isolated and syndromic brachydactylies: diagnostic value of hand X-rays. Diagn Interv
3. Imaging 2015; 96: 443–448. doi: 10.1016/j.diii.2014.12.007.
4. Bell J. On brachydactyly and symphalangism. In: Penrose LS, ed. Treasury of human inheritance. Vol. 5. London: Cambridge University Press; 1951. p. 191–201.
5. Williams KD, Nahhas RW, Cottom CR, et al. Evaluation of qualitative methods for phenotyping brachymesophalangia-V from radiographs of children. Am J Hum Biol 2012; 24: 68–73. doi: 10.1002/ajhb.22205.
6. Williams KD, Blangero J, Cottom CR, et al. Heritability of brachydactyly type A3 in children, adolescents, and young adults from an endogamous population in Eastern Nepal. Hum Biol 2007; 79: 609–622. doi: 10.1353/hub.2008.0016.
7. Chen Y, Yin M, Lu Y, et al. Short stature with brachydactyly caused by a novel mutation in the IHH gene and response to 4-year growth hormone therapy: a case report. Transl Pediatr 2024; 13: 856–863. doi: 10.21037/tp-23-578.
8. Vasques GA, Funari MFA, Ferreira FM, et al. IHH gene mutations causing short stature with nonspecific skeletal abnormalities and response to growth hormone therapy. J Clin Endocrinol Metab 2018; 103: 604–614. doi: 10.1210/jc.2017-02026.
9. Wu H, Li Y, Li H. Brachydactyly type A3 is more commonly seen in children with short stature but does not affect their height improvement by growth hormone therapy. Front Endocrinol (Lausanne) 2022; 13: 824315. doi: 10.3389/fendo.2022.824315.
10. Schwabe GC, Türkmen S, Leschik G, et al. Brachydactyly type C caused by a homozygous missense mutation in the prodomain of CDMP1. Am J Med Genet A 2004; 124A: 356–363. doi: 10.1002/ajmg.a.20349. 
11. Li Q, Bai F, Chen S. Frameshift mutation in a Chinese patient with brachydactyly type C involving the third metacarpal: a case report. Orthop Surg 2022; 14: 2386–2390. doi: 10.1111/os.13383.
12. Palczewska I, Niedźwiedzka Z. Somatic development indices in children and youth of Warsaw. Med Wieku Rozwoj 2001: 5: 18–118. [Article in Polish].
13. Grimberg A, DiVall SA, Polychronakos C, et al. Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016; 86: 361–397. doi: 10.1159/000452150. 
14. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev 2007; 28: 219–251. doi: 10.1210/er.2006-0039.
15. Kucharska A, Witkowska-Sędek E, Erazmus M, et al. The effects of growth hormone treatment beyond growth promotion in patients with genetic syndromes: a systematic review of the literature. Int J Mol Sci 2024; 25: 10169. doi: 10.3390/ijms251810169.
16. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995, 80: 1532–1540. doi: 10.1210/jcem.80.5.7538145.
17. Romer TE, Walczak M, Wiśniewski A, et al. Children with growth disorders qualified in Poland for growth hormone therapy. Pediatr Prakt 2001, 9: 41-54. [Article in Polish].
18. Leczenie niskorosłych dzieci z somatotropinową niedoczynnością przysadki. Załącznik B.19 do Obwieszczenia nr 65 Ministra Zdrowia w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia oraz wyrobów medycznych. Available at: https://www.gov.pl/attachment/c2022097-fbd3-43fc-8629-f968b509df5f (accessed 31 Mar 2021). [In Polish].
Udostępnij
without publication fees
Zintergrowane z
integrated with publons
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications